Novavax | NVAX - Capital De Empréstimo





Capital De Empréstimo Alterar Data
Adma Biologics USD 193.58M 124.25M 2026-03
Agenus USD 169.66M 146.06M 2025-12
AstraZeneca USD 25.96B 177M 2026-03
BioCryst Pharmaceuticals USD 395.2M 33.48M 2026-03
Cassava Sciences USD 0 0 2024-12
Geron USD 119.83M 286K 2026-03
GlaxoSmithKline GBP 14.01B 696M 2026-03
MannKind USD 548.07M 371K 2026-03
Merck USD 46.67B 77M 2026-03
Minerva Neurosciences USD 0 86.58M 2024-09
Moderna USD 603M 7M 2026-03
Novartis USD 37.45B 7.86B 2026-03
Novavax USD 246.3M 200K 2025-12
Pfizer USD 60.57B 1.08B 2026-03
Sanofi EUR 13.84B 1.88B 2026-03
Sarepta Therapeutics USD 838.16M 9.19M 2026-03
TG Therapeutics USD 745.14M 499.5M 2026-03